Mesenchymal stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy

Paolo Giuseppe Limoli  
Low Vision Research Centre of Milan

Celeste Limoli  
Low Vision Research Centre of Milan

Enzo Maria Vingolo  
Sapienza University of Rome: Universita degli Studi di Roma La Sapienza

Federica Franzone  
Sapienza University of Rome: Universita degli Studi di Roma La Sapienza

Marcella Nebbioso (✉ marcella.nebbioso@uniroma1.it)  
Sapienza University of Rome: Universita degli Studi di Roma La Sapienza  https://orcid.org/0000-0002-5512-0849

Research Article

Keywords: Adipose-derived stem cell, autograft, cell surgery, glaucoma, glaucomatous optic neuropathy, growth factor (GF), Limoli Retinal Restoration Technique (LRRT), mesenchymal stem cell (MSC), platelet-rich plasma, stem cells

DOI: https://doi.org/10.21203/rs.3.rs-312110/v1

License: ☇️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Glaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma. Recently, growth factors (GF) have been shown to produce retinal neuroenhancement. The suprachoroidal autograft of mesenchymal stem cells (MSC) by Limoli Retinal Restoration Technique (LRRT) has proven to achieve retinal neuroenhancement by producing GF directly into the choroidal space. This retrospectively registered clinical study investigated the visual function changes in patients with GON treated with LRRT. Methods: Twenty-five patients (35 eyes) with GON in progressive disease conditions were included in the study. Each patient underwent a comprehensive ocular examination, including analysis of Best Corrected Visual Acuity (BCVA) for far and near visus, sensitivity by Maia microperimetry, and the study of the spectral domain-optical coherence tomography (SD-OCT). The patients were divided into two groups: a control group, consisting of 21 eyes (average age 72.2 years, range 50–83) and an LRRT group, consisting of 14 eyes (average age 67.4, range 50–84). Results: After 6 months the BCVA, close-up visus, and microperimetric sensitivity significantly improved in the LRRT-treated group (p < 0.05), whereas the mean increases were not statistically significant in controls (p > 0.5). Conclusions: Patients with GON treated with LRRT showed a significant increase of visual performance (VP) both in BCVA and sensitivity and an improvement of residual close-up visus, in the comparison between the LRRT results and the control group. Further studies will be needed to establish the actual significance of the reported findings.

Background

Glaucoma causes retinal ganglion cell (RGC) layer degeneration, impairing visual function.

It has been estimated that over 100 million people will be affected by glaucoma in 2040 [1]. Glaucoma affects the sensory input towards the visual cortex resulting in progressive visual field loss [2]. Anatomical degeneration can be found since the early stages of glaucoma also within the lateral geniculate nucleus and visual cortex [2]. The critical intraocular pressure (IOP), representing chronic stress, is considered the main cause of damage to the RGC layer and nerve fibers. IOP has been demonstrated to reduce bidirectional axonal transport over time, according to both individual susceptibility and clinical presentation [3]. The damage seems to initially involve the unmyelinated RGC axons within the optic nerve head and then the RGC bodies, resulting in glaucomatous optic neuropathy (GON). In that degenerative phase, thinning of the neuroretinal rim and pathological cupping have been observed, resulting in specific nervous fiber damage corresponding to visual field defects.

Numerous pathogenetic mechanisms have been proposed to explain the apoptotic loss of RGCs in glaucoma: microcirculatory ischemia, hyperproduction of reactive oxygen species (ROS), impaired bidirectional axonal transport, parainflammation, excitotoxicity, neurotrophic factors reduction, and electrical activity reduction [2–5]. Currently, the most frequently used treatment for GON is IOP control,
being considered the main risk factor [3]. Hypotensive therapies, together with neurotrophic supplements, represent the recommended treatment for patients with GON to stop or slow down neurodegeneration.

The recent appearance of cell therapy in regenerative medicine has represented a promising tool in glaucoma therapy [6]. On the one hand, embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) have been used in preclinical and clinical studies to replace dead or diseased RGCs, but, although expressing RGC markers, they have not shown to effectively restore retinal connections, as they remain close to the injection site [6].

On the other hand, mesenchymal stem cells (MSC) can be exploited for their paracrine secretion of different molecules that have been shown to activate RGC-intrinsic regenerative programs after optic nerve injury, promoting cell survival and axonal regeneration [7]. Specifically, the effectiveness of MSCs is expressed through several mechanisms, including hemorheological, anti-oxidative, anti-inflammatory, anti-apoptotic, neurotrophic and cytoprotective ones [3, 6, 7]. These mechanisms clinically could lead to the improvement of visual performance (VP) and the overall prognosis of glaucoma.

In this context, an autograft of MSCs in the suprachoroidal space according to the Limoli Retinal Restoration Technique (LRRT), consisting of the following triad, could be effective: adipose stromal cells (ASCs), adipose-derived stem cells (ADSCs) contained in the stromal vascular fraction (SVF) of adipose tissue, and platelets (PLT) recovered from the platelet-rich plasma (PRP) [8–13] (Fig. 1).

This study aimed to evaluate both the efficacy and safety of LRRT suprachoroidal MSC graft in patients with GON.

**Materials And Methods**

**Study participants**

This retrospectively registered study was performed at the Low Vision Center in Milan between January 2015 and September 2019. The study was performed in accordance with the tenets of the 1964 Declaration of Helsinki and was approved by the Institutional Review Board of the Low Vision Academy (No. 2014/MC104, 4 October 2014).

Written informed consent was obtained from all the patients prior to enrollment. Individuals who met the following inclusion criteria were recruited for the study:

Diagnosis of GON highlighted by microperimetry or, when necessary, coherence optical tomography (OCT).

- Excavated optic papilla with cup/disc < 0.6;
- Good therapeutic balance (IOP ≤ 15 mmHg) obtained with hypotonizing therapy; the pressure must be corrected also after LRRT surgery.
Best-corrected visual acuity (BCVA) between +1 and 0 logarithm of the minimum angle of resolution (LogMAR);
Age between 50 and 84 years old;
Stable eye conditions without previous surgery or ocular trauma.

Subjects who met any of the following criteria were excluded from the study:

- Bad therapeutic balance (IOP > 15 mmHg) obtained with hypotonizing therapy; IOP must be also corrected after LRRT surgery.
- Refractive error ≥ 6 diopters of myopia, hypermetropia, and astigmatism;
- Presence of cataract or other media opacity that could interfere with a functional response;
- Presence of chorioretinal diseases including macular pucker with the altered foveal area, age-related macular diseases (AMD), or eredodistrophy, etc.;
- Intravitreal injection treatment and/or intraocular surgery;
- Inability to provide written informed consent;
- Inability to attend all follow-up visits;
- Systemic diseases including multiple sclerosis, epilepsy, vasculitis, Parkinson's disease, renal and hepatic diseases, malignant neoplasms, decompensated diabetes mellitus, etc.

All the eyes enrolled in this study were divided into two groups: the LRRT group who underwent autologous suprachoroidal graft of mesenchymal cells, and the control group of GON patients who did not undergo LRRT surgery.

Participants used as control were matched with GON patients according to the sensitivity alteration measured by microperimetry.

**Ophthalmologic examination**

The diagnosis of GON was established for each patient by the clinical analysis of visual performances (VP). Then, evaluation by slit-lamp biomicroscopy with and without dilatation, applanation tonometry, and retinal mapping with an indirect ophthalmoscope were performed. Also, BCVA, close-up visus, sensitivity measured by microperimetry (MY) with Maia 100809 (CenterVue S.p.A., Padua, Italy), spectral domain-optical coherence tomography (SD-OCT) with Cirrus 5000 (Carl Zeiss Meditec AG, Jena, Germany), and ocular electrophysiology with the Retimax electromedical system (C.S.O. Srl, Scandicci, Italy) were performed. All the ophthalmologic analyses were carried out by the same examiner at baseline (T0) and 6 months (T180) in both groups. Finally, the subjective improvement of VP in the LRRT group at 6 months after surgery was reported. BCVA was always measured according to the standards recommended by the early treatment diabetic retinopathy study charts (ETDRS) at 4 meters and expressed in logMAR. The visual acuity for near distance (close-up visus) was recorded in points (Pts). Microperimetry was performed using a Maia apparatus (Centervue spa, Padua, Italy) with images acquired by scanning laser ophthalmoscopy. Sensitivity was measured from 0 to 25 decibel (dB), and the
color was coded. The field of the infrared image was 36° x 36°, and perimetry was performed in a field of 30° x 30° with a luminance of 4 asb. The Full-Threshold 4-L test was used to assess the retina in detail.

**LRRT: cell isolation and grafting procedures**

The autograft of MCs in the suprachoroidal space, i.e., LRRT consisted of the following triad: ASCs, ADSCs contained in SVF of adipose tissue, and platelets obtained from the PRP. ASCs were collected from the orbital fat during the surgical procedure according to previously published methods [8]. A scleral pocket with deep sclerectomy was created in each patient’s eye to expose the surface of the choroidal space [9].

After exposing the choroid, the pedicle of adipose tissue derived from the orbital space was placed on the choroid’s surface (Fig. 1). ADSCs contained in the SVF were grafted in the suprachoroidal space. The SVF was isolated from the abdominal fat according to the Lawrence and Coleman technique [14]. Briefly, 10 mL of adipose tissue were manually harvested from the abdominal subcutaneous layer of each patient using a 3 mm blunt cannula connected to a locking syringe. After adding 50 mL of saline solution to the freshly harvest lipoaspirate for 10 minutes to eliminate the blood component, the supernatant was extracted and centrifuged at 1500xg for 5 minutes at 20°C in order to isolate SVF from the mature adipocytes, connective tissues, cellular debris, and oil.

The platelets were obtained from PRP gel according to established methodologies [9]. Eight mL of human peripheral blood was collected with a 22 G needle and put in a Regen-BCT tube (RegenKit; RegenLab, Le Mont-sur-Lausanne, CH) for PRP preparation. The collected blood was centrifuged at 1500 x g for 5 min at 20°C in order to isolate the PRP.

The adipose pedicle was infiltrated with platelets derived from the PRP gel (Fig. 1).

Finally, a mixture of ADSCs from the SVF and PRP was used to saturate the residual volume of the scleral pocket, where the pedicle of adipose tissue-derived from the orbital space was previously placed (Box 1).

**Box 1. Surgical phases of Limoli Retinal Restoration Technique (LRRT).**

- Anchoring of the sclera with 6 – 0 silk suture, near the inferior-temporal limbus, and globe deviated to the superonasal quadrant.
- Opening of the subconjunctival and Sub-Tenon’s space at 11 mm from the inferior-temporal limbus, using 5.5” Westcott Tenotomy curved scissors.
- Insert the Limoli-Basile conjunctival retractor in the space to make a scleral surgical field.
- To pre-cut the flap on the side in the sclera at 8 mm from the limbus using a 5-mm crescent knife angled up with the flap hinge always radial and to the left of the surgeon.
- Open a deep scleral flap of about 5 x 5 mm at the inferotemporal quadrant, maintaining the radial hinge. The sclerectomy has to be deep enough to allow viewing the color of the choroid.
• Remove a little operculum in the distal part of the flap in order to facilitate blood circulation in the subsequent suprachoroidal autograft.
• Extract the orbital fat with forceps from a gap above the inferior oblique muscle. The fat must sufficiently be vascularized to allow it to survive after its implantation
• Place the autologous fat flap on the choroidal bed and suture with choroidal 6/0 polyglactin fiber at the proximal edge of the door.
• Suture the scleral flap to avoid compression on the fat pedicle or its nutrient vessels.
• Infiltrate the stroma of the fat pedicle with 1 mL of PRP gel (obtained by centrifugation of the blood material, separation of the component, and platelet degranulation) using a 30 G angled (30°) cannula.
• Remove the conjunctival retractor. Suture the conjunctiva with 6/0 polyglactin fiber.
• Leave a small flexible plastic tube to insert the autologous ADSCs in the space between the flap, the choroid, and the suprachoroidal autograft, before closing.
• Fill the remaining space between the autologous fat graft, choroid, and scleral flaps with 0.5 cc of ADSCs in SVF and 0.5 of PRP using a 25 G cannula and close the suture.
• After surgery, administer three days of antibiotic therapy with 500 mg of azithromycin. Also, provide eye drop therapy with an antibiotic and steroid combination, such as Chloramphenicol and Betamethasone, for about 15–20 days.

Cell identification by flow cytofluorimetry

Flow cytometry analyses were performed in order to identify the phenotypic characteristics of the population of cells within the graft, specifically ADSCs and platelets. PRP and SVF were obtained from patients of the LRRT group who underwent LRRT surgery and were isolated under fresh conditions. SVF was manually isolated from each patient’s lipoaspirate in a clean room near the operating room, according to a previously described method [15]. Briefly, the adipose portion of the lipoaspirate was washed with the phosphate-buffered saline (PBS; Biological Industries) and mixed with 2.5 mg/mL of collagenase type II (Worthington Biochemical Corporation, Lakewood, NJ) for enzymatic digestion. The collagenase/adipose mixture was placed in a 37°C water bath for 30 minutes in order to create a single-cell suspension and then filtered through a 100 µ cell strainer and finally a 45 µ mesh. It was centrifuged for 5 minutes at 1200 x g to collect the cellular SVF as a pellet. Once isolated, characterization of the cell composition of freshly-isolated SVF was obtained by multi-color flow cytometry (CytoFLEX Flow Cytometer, Backman Coulter, USA) that allows the in-vitro identification of the surface marker expression of the cells. The panel of cell surface antigens was chosen in agreement with the International Federation for Adipose Therapeutics and Science (IFATS) and International Society for Cellular Therapy (ISCT) recommendations [16]. The immunophenotypic analyses were performed to confirm the mesenchymal nature of isolated cells. The following fluochrome-labeled monoclonal antibodies were used for SVF analysis: CD31-PE, CD34-PC, and CD45-APC (Backman Coulter, USA). The markers were used in combination with ViaKrome (Beckman Coulter, USA), which determines cell viability, excluding debris and
dead cells induced by the isolation protocol. Cells were incubated with specific mAbs for 15 minutes. At least 105 cells were acquired from each sample. The software CytEpert Version 2.2.0.97, CytoFLEX (Beckman Coulter, Inc) was used to create dot plots and to calculate the cell composition percentages according to the profile of the surface marker expression. Immunophenotyping of platelets by flow cytometry was performed on platelets in PRP. The following markers were used for platelet analysis: anti-CD41-FITC and CD61-PE [17].

**Statistical analysis**

All statistical analyses were performed using software SPSS Statistics (version 20.0, SPSS Inc, Chicago, IL). Data were summarized with the mean ± standard deviation (SD) and minimum and maximum (min-max) values were also reported. Student's *t*-test was used to compare values between controls and the study group. Paired *t*-test was run to compare study subjects and controls at baseline and after 6 months. A *p* value < 0.05 was considered statistically significant.

**Results**

**Patient Characteristics**

A total of 35 eyes from 25 patients affected by GON (10 females and 15 males; mean age 70.7 ± 9.9 years, range 50–84 years) met the inclusion criteria and were enrolled in the study. Twenty-one eyes of the total composed the control group (8 males and 7 females; mean age 72.2 ± 9.6 years, range 50–83 years), while the remaining 14 eyes constituted the LRRT group of patients (7 males and 3 females; mean age 69.4 ± 9.2 years; range 50–84 years). Two patients from the latter group were excluded from the analysis because of the close-up visus that was not assessable, and the BCVA that was greater than 1 LogMAR. The baseline characteristics are summarized in Table 1.

| Parameters of patients | LRRT Group | Controls |
|------------------------|------------|----------|
| Number eyes            | 14 (10)    | 21 (15)  |
| Age, years (range)     | 69.4 (50–83) | 72.2 (50–84) |
| Sex, number (%), Male  | 7 (70)    | 8 (54)   |
| Sex, number (%), Female| 3 (30)    | 7 (46)   |

No adverse event associated with the surgery either intra-operatively or post-operatively was observed throughout the period. Mean values of the IOP recorded before and after surgery did not change significantly. All completed 6 months of evaluation.

**Phenotype of platelets and freshly isolated SVF**
The positive expression for cell surface antigens CD61 and CD41 identified PLTs. We observed that the PRP contained a mean of $79.2 \pm 13.7\%$ PLT on a total of $10^5$ cells.

The positive expression for cell surface antigens CD34 and negative expression for CD31 and CD45 identified ADSCs. The percentage of the phenotypically identified ADSC population was $44.9\% \pm 11\%$ on a total of $10^5$ cells and the ADSC/$\mu$L was $590.3/\mu$L ($127.2–1485.3/\mu$L) (Fig. 2).

**BCVA**

After 6 months, the BCVA went from 0.0947 to 0.0937 logMAR in the control group with a mean increase of -0.001 (+ 1.09%; $p > 0.05$) and from 0.213 to 0.155 logMAR in the LRRT group with a statistically significant increase of -0.0582 (+ 27.32%; $p = 0.0264$) (Fig. 3; Table 2). The difference between the 6-month increase in LRRT treated group compared to evolution in the control group is considered to be statistically significant ($p = 0.0353$).

**Close-up Visus**

After 6 months, the close-up visus went from 6.57 to 6.9 pts in the control group with a mean reduction of -0.33 pts (-5.02%; $p > 0.05$) and from 10.21 to 8.29 pts in the LRRT-treated group with a mean increase of 1.93 (+ 18.81%; $p > 0.05$) (Fig. 4, Table 2). However, the latter increase did not reach statistical significance. The difference between the 6-month increase in the LRRT-treated group compared to the evolution in the control group is not considered to be statistically significant ($p = 0.0818$).

**Microperimetry**

After 6 months, sensitivity went from 13.20 to 12.64 dB in the control group with a mean reduction of -0.56 dB (-4.24%; $p > 0.05$) and from 10.00 to 11.12 in the LRRT-treated group with a statistically significant increase of 1.12 dB (+ 11.24%; $p = 0.0033$) (Figs. 5 and 6, Table 2). The difference between the 6-month increase in the LRRT-treated group compared to the evolution in the control group is considered to be statistically significant ($p = 0.0014$).
Table 2
Best-corrected visual acuity (BCVA), close-up visus, and sensitivity in Limoli Retinal Restoration Technique (LRRT) and Control groups. Values between controls and LRRT groups were compared by Student’s t-test at baseline (T0) and 6 months (T180).

|                        | LRRT Group (N = 14) | Control (N = 21) |
|------------------------|---------------------|------------------|
|                        | Means ± SD         | ∆ ± SD           | P◊     | Means ± SD       | ∆± SD   | P◊    | P°     |
|                        | T1     | T180    | T1    | T180 |
| BCVA,                  | 0.213  | 0.154   | 0.058 | 0.0264*          | 0.095  | 0.094 | -0.001 | 0.9446 | 0.0353* |
| LogMAR                 | ± 0.295 | ± 0.246 | ± 0.087 | ± 0.135 | ± 0.104 | ± 0.067 |
|                        | 27.3%  | 1.1%    |
| Close up visus, pts    | 10.21  | 8.29    | 1.93  | 0.2009          | 6.57   | 6.90  | -0.33  | 0.4057 | 0.0818 |
|                        | ± 7.44 | ± 5.59  | ± 5.37 | ± 1.47 | ± 1.92 | ± 1.80 |
|                        | 18.8%  | -5.02%  |
| Sensibility, dB        | 10.00  | 11.12   | 1.12  | 0.0033*         | 13.20  | 12.64 | -0.56  | 0.1093 | 0.0014* |
|                        | ± 5.82 | ± 6.00  | ± 1.17 | ± 5.90 | ± 5.83 | ± 1.53 |
|                        | 11.2%  | -4.2%   |

SD: Standard Deviation; logMAR: logarithm of the minimum angle of resolution; pts: points; dB: deciBel; ∆ mean changes from T0 to T180; *Statistical significance with p value ≤ 0.05; ◊ intergroup comparison; ° Comparison between groups.

**Compliance**

The subjective experience of all LRRT treated patients was surveyed. At 6 months, the VP increased in 11 eyes out of 14 (79%) and remained unvaried in 3 eyes (21%). Notably, the VP worsened in no eyes (Fig. 7).

**Discussion**

In this study, patients affected with GON received the LRRT treatment to preserve the residual VP. All of the eyes in the study group showed improvement in BVCA, sensitivity, and residual close-up visus with no ocular and systemic complications; whereas the majority of the eyes in the control group showed a decrease in the same measured parameters. The improvements were consistent through the 6 months follow-up.
GON is currently recognized as a progressive neurodegenerative disease, resulting in due course permanent visual loss [2]. Up to date, there are no curative treatments, however many potential options are being investigated in the clinical setting, including retinal prostheses, gene therapies, and cell-based treatments. Among these different therapeutic alternatives, growing research interest has been developed towards the MSCs, i.e. adult stromal cells, as promising candidates for cell therapy in retinopathies [6–8, 18].

These cells are ubiquitously distributed in the body and play a key role in organogenesis, tissue remodeling and repair [18]. A growing body of evidence points that MSCs can restore VP in different ocular degenerative disorders through various therapeutic pathways involving cell differentiation to replace the lost cells, paracrine activity to trigger cell survival and repair, and modulation of the local immune response [6–8, 18].

They are characterized by multipotency, as they have been shown to differentiate into several cell types, including adipocytes, chondrocytes, osteoblasts, vascular endothelial cells, cardiomyocytes, beta-pancreatic cells, hepatocytes, and, under specific conditions, also into retinal neuron-like, including retinal progenitors and photoreceptors [19]. However, MSCs are clinically attractive for the paracrine secretion of a broad range of bioactive molecules such as cytokines, chemokines, and GFs [20–22]. To name a few, they can secrete basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), placental growth factor (PIGF), transforming growth factor-β (TGF-β), hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), interleukin (IL), angiogenin, ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF) [18, 23]. Also, MSCs can release extracellular vesicles and exosomes that carry mRNA, microRNA, proteins, mitochondrial components, and ribosomes [24]. It is known that exosomes help communication between MSCs and the surrounding niches and can activate the proliferation and differentiation of native stem cells [24].

These biological mediators are well known for providing a vital microenvironment by inducing gene expression changes that lead to neuroprotective, regenerative, anti-inflammatory, and anti-apoptotic effects; hence, they can support cell survival and rescue the damaged tissue [6–8, 18]. This complex interplay has been shown to cause functional neuro-enhancement of the residual retinal cells and to regulate regeneration by reversing cell death or damage in different diseases. Especially due to their paracrine trophic activity, MSCs have emerged as trending regenerative biologic agents for retinopathies [18].

As defined by the International Society for Cellular Therapy, MSCs are characterized by a set of negative and positive surface markers: they express CD105, CD73, CD34, and CD90 and lack CD45, CD14, CD11, CD79, CD19, and HLA-DR. MSCs also express other surface markers, such as CD44, CD166, Stro-1, CD106 and CD146 [16].
MSCs can be isolated from adult and fetal tissues, including bone marrow, adipose tissue, Wharton’s jelly, dental pulp, and placenta [20, 25]. ADSCs have been emerging as ideal MSCs among the other cell sources because of their sustainable costs, manageability, easy harvesting, and wide distribution in the adult tissues. Compared with bone marrow, adipose tissue contains a higher number of MSCs and of pericytes, which are the precursors to MSCs, and a lower amount of leukocytes [20, 25]. Furthermore, the adipose tissue is one of the most attractive sources for MSCs due to the lack of ethical concerns involved in their application, and the high paracrine trophic and immunomodulatory effects. Most notably, ADSCs have been shown to have no risks of uncontrolled growth and malignant transformation, no rejection or immune reactions, demonstrating their long-term efficacy and compatibility in the transplanted tissue [22, 25].

For all the provided reasons, ADSCs are ideal for autologous cell transplants and we chose to use them for our surgical procedure.

The LRRT is a cell therapy consisting of autologous ADSCs within the SVF, ASCs, and PRP [9]; it is administered intra-ocularly with a supra-choroidal delivery method.

Alongside ADSCs, also ASCs have shown regenerative potential as well as autologous PRP that is a source of growth factors [8, 25].

Freshly isolated cells were subjected to flow cytometry analyses to confirm the immunophenotyping characterization of ADSCs within SVF and PRP.

Different routes of administration of MSCs have been explored in different clinical studies for the management of degenerative retinal diseases. We used the suprachoroidal method, which is reported to have no serious complications and is considered to be safer compared to the intravitreal or subretinal applications [11].

The suprachoroidal area has been shown as natural drug storage and an immune-protected region [9–13]. The GFs secreted by the ADSCs can effectively pass through that space and reach the retinal target without producing immune reactions, making the suprachoroidal region ideal as the site of MSCs administration.

The effect of ADSCs is thought to be related to the expression of several GFs, including bFGF, BDNF, NGF, CNTF, GDNF, and HGF [3, 6, 7]. GFs secreted by MSCs in the suprachoroidal space can either trigger the retinal cells in the quiescent phase to re-enter the cell cycle and activate the progenitor cells or act directly on the damaged cells supplying neuroprotection and reducing the retinal oxidative damage. GFs have been shown to inhibit apoptosis in the diseased retina, to mediate a neuro-cytoprotective action, and to suppress retinal chronic inflammation that occurs in glaucoma through an anti-inflammatory and immunomodulating action. Furthermore, several in vivo and in vitro studies have shown MSCs-mediated pleiotropic activity in stimulating angiogenesis in ischemic disease, myelination, dendritic and axonal regeneration through IGF secretion and mTOR pathway activation [20–29].
In this way, the can promote RGC survival and stimulate both axonal regeneration and myelination in the optic nerve, restoring both dendritic and synaptic connections with bipolar and amacrine cells [23–27].

According to these findings, MSCs might promote the RGC function and survival through the paracrine release of GFs, exosomes, and microvesicles over time, slowing retinal degeneration.

These biochemical mechanisms could underlie the positive clinical results we observed following the autologous MSC graft performed by LRRT treatment in the suprachoroidal space in patients affected with GON.

The LRRT treatment has been applied in other studies of our group in retinal diseases, such as retinitis pigmentosa, AMD, and optic neuropathies, and it has been shown its safety and effectiveness with improvements of both VP and electroretinographic parameters [9–12]. In this clinical study, the LRRT demonstrated healing potential in patients with GON.

In accordance with our results, many investigators evaluated the safety and efficacy of the MSCs use for retinal diseases and suggest MSCs-mediated neuroprotection [13, 30, 31].

Oner et al. [13] showed that the suprachoroidal implantation of ADSCs in patients with optic nerve disease caused functional improvement in VP in terms of visual acuity, visual field, and mfERG recordings. These outcomes are believed to be related to the paracrine secretion of neurotrophic and angiogenic GFs from ADMSCs and angiogenic GFs from PRP, suppressing the inflammation and protecting RGCs from death.

In Brazil, Siqueira et al. [31] conducted a study with intravitreal injection of bone-marrow derived stem cells in patients with RP, showing the safety of the cell therapy and observing an increased quality of life.

Finally, a Californian group [32] obtained similar results with the intravitreal use of BMDSCs in patients affected with retinal vascular occlusion, non-exudative age-related macular degeneration, or retinitis pigmentosa. The investigators assessed the safety and feasibility of cell therapy, showing the important role that MSCs may play in tissue repair.

Alongside ADSCs, also ASCs have shown regenerative potential as well as autologous PRP that is a source of growth factors [8, 25].

Freshly isolated cells were subjected to flow cytometry analyses to confirm the immunophenotyping characterization of ADSCs within SVF and PRP.

Different routes of administration of MSCs have been explored in different clinical studies for the management of degenerative retinal diseases. We used the suprachoroidal method, which is reported to have no serious complications and is considered to be safer compared to the intravitreal or subretinal applications [11].
The suprachoroidal area has been shown as natural drug storage and an immune-protected region [9–13]. The GFs secreted by the ADSCs can effectively pass through that space and reach the retinal target without producing immune reactions, making the suprachoroidal region ideal as the site of MSCs administration.

The effect of ADSCs is thought to be related to the expression of several GFs, including bFGF, BDNF, NGF, CNTF, GDNF, and HGF [3, 6, 7]. GFs secreted by MSCs in the suprachoroidal space can either trigger the retinal cells in the quiescent phase to re-enter the cell cycle and activate the progenitor cells or act directly on the damaged cells supplying neuroprotection and reducing the retinal oxidative damage. GFs have been shown to inhibit apoptosis in the diseased retina, to mediate a neuro-cytoprotective action, and to suppress retinal chronic inflammation that occurs in glaucoma through an anti-inflammatory and immunomodulating action. Furthermore, several in vivo and in vitro studies have shown MSCs-mediated pleiotropic activity in stimulating angiogenesis in ischemic disease, myelination, dendritic and axonal regeneration through IGF secretion and mTOR pathway activation [16, 20–29].

In this way, the can promote RGC survival and stimulate both axonal regeneration and myelination in the optic nerve, restoring both dendritic and synaptic connections with bipolar and amacrine cells [23–27].

According to these findings, MSCs might promote the RGC function and survival through the paracrine release of GFs, exosomes, and microvesicles over time, slowing retinal degeneration.

These biochemical mechanisms could underlie the positive clinical results we observed following the autologous MSC graft performed by LRRT treatment in the suprachoroidal space in patients affected with GON.

The LRRT treatment has been applied in other studies of our group in retinal diseases, such as retinitis pigmentosa, AMD, and optic neuropathies, and it has been shown its safety and effectiveness with improvements of both VP and electroretinographic parameters [9–12]. In this clinical study, the LRRT demonstrated healing potential in patients with GON.

In accordance with our results, many investigators evaluated the safety and efficacy of the MSCs use for retinal diseases and suggest MSCs-mediated neuroprotection [13, 30–32].

Oner et al. [13] showed that the suprachoroidal implantation of ADSCs in patients with optic nerve disease caused functional improvement in VP in terms of visual acuity, visual field, and mfERG recordings. These outcomes are believed to be related to the paracrine secretion of neurotrophic and angiotrophic GFs from ADMSCs and angiotrophic GFs from PRP, suppressing the inflammation and protecting RGCs from death.

In Brazil, Siqueira et al. [31] conducted a study with intravitreal injection of bone-marrow derived stem cells in patients with RP, showing the safety of the cell therapy and observing an increased quality of life.
Finally, a Californian group [33] obtained similar results with the intravitreous use of BMDSCs in patients affected with retinal vascular occlusion, non-exudative age-related macular degeneration, or retinitis pigmentosa. The investigators assessed the safety and feasibility of cell therapy, showing the important role that MSCs may play in tissue repair.

The study has some limitations. First, our sample size was small and the study was not masked. A larger number of patients will be necessary to evaluate the effects of this therapy.

Second, the duration of action of LRRT treatment is unknown. Even though long-term research is necessary to determine the duration of efficacy, PRP booster injections after 12 months have been shown to maintain the outcomes. Another limitation of the study is that we do not measure whether additional treatments such as electrical stimulation may increase MSCs activity. The latter limitation forms the basis for near-future studies.

**Conclusions**

The LRRT treatment has proven safe and effective in treating patients affected with GON.

In our experience, both visual acuity and retinal sensitivity measurements showed statistically significant improvements in 80% of GON patients after LRRT during the follow-up period of 6 months, and no ocular or systemic effects were reported. Therefore, autologous MSC graft combined with PRP into the suprachoroidal space could contribute to restoring optic nerve function, improving the clinical, prognostic, and rehabilitative aspects in patients affected with GON, that currently have no curative treatment options.

Further studies are needed to validate our findings and to unveil the potential of MSCs as therapeutic agents in regenerative medicine especially for degenerative retinal and optic nerve diseases.

**Abbreviations**

ADSC: adipose-derived stem cells; AMD: age-related macular diseases; ASC: adipose stromal cells; BCVA: best corrected visual acuity; BDNF: brain-derived neurotrophic factor; bFGF: basic fibroblast growth factor; CNTF: ciliary neuro-trophic factor; dB: deciBel; ESC: embryonic stem cell; ETDRS: early treatment diabetic retinopathy study charts; GDNF: glial cell-derived neurotrophic factor; GF: growth factors; GM-CSF: granulocyte-macrophage colony-stimulating factor; GON: glaucomatous optic neuropathy; HGF: hepatocyte growth factor HIF-1; HIF-1: hypoxia-inducible factor 1; IGF: insulin-like growth factor; IOP: intraocular pressure; iPSC: induced pluripotent stem cell; logMAR: logarithm of the minimum angle of resolution; LRRT: Limoli Retinal Restoration Technique;

M-CSF: macrophage colony-stimulating factor; MSC: mesenchymal stem cell; NGF: nerve growth factor; PLT: platelets; PRP: platelet rich plasma; pts: points or print size; RGC: retinal ganglion cell; RNA: ribonucleic acid; ROS: reactive oxygen species; RP: retinitis pigmentosa; RPE: retinal pigment epithelium;
SD-OCT: spectral domain-optical coherence tomography; SVF: stromal vascular fraction; TGF-β: transforming growth factor-β; TNF-α: tumor necrosis factor-α; VEGF: vascular endothelial growth factor; VP: visual performances.

**Declarations**

**Authors’ Contributions**

Conceptualization and writing P.G.L.; data analysis, M.N.; investigation C.L.; data curation E.M.V; resources F.F.

**Acknowledgements**

Not applicable

**Compliance with ethics guidelines**

This retrospectively registered study was performed at the Low Vision Center in Milan between January 2015 and September 2019. The study was performed in accordance with the tenets of the 1964 Declaration of Helsinki and was approved by the Ethics committee of the Institutional Review Board of the Low Vision Academy (No. 2014/MC104, 4 October 2014). Written informed consent was obtained from all the patients prior to enrollment.

**Funding**

This research received no external funding.

**Availability of data and materials**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Consent for publication**

Not applicable

**Competing interests**

None

**Conflicts of Interest**

The authors declare no conflict of interest. P.G. Limoli, None; C. Limoli, None; E.M. Vingolo, None; F. Franzone, None; M. Nebbioso, None.
References

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014, 121, 2081-90.

2. Calkins DJ. Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog. Retin. Eye Res. 2012, 6, 702–719.

3. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012, 119, 979–986.

4. Chua J, Vania M, Cheung CM, et al. Expression profile of inflammatory cytokines in aqueous from glaucomatous eyes. Vis. 2012, 18, 431-438.

5. Soto I, Howell GR. The complex role of neuroinflammation in glaucoma. Cold Spring Harb. Perspect. Med. 2014, 4, a017269.

6. Calkins DJ. The challenge of regenerative therapies for the optic nerve in glaucoma. Exp. Eye Res. 2017, 157, 28–33.

7. Jones MK, Lu B, Girman S, Wang S. Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases. Retin. Eye Res. 2017, 58, 1-27.

8. Osborne A, Sanderson J, Martin KR. Neuroprotective effects of human mesenchymal stem cells and platelet-derived growth factor on human retinal ganglion cells. Stem Cells. 2018, 36, 65-78.

9. Limoli PG, Limoli C, Vingolo EM, Limoli C, Scalinci SZ, Nebbioso M. Regenerative therapy by suprachoroidal cell autograft in dry age-related macular degeneration: preliminary in vivo report. J. Vis. Exp. 2018, 132, e56469.

10. Limoli PG, Vingolo EM, Limoli C, Nebbioso M. Stem cell surgery and growth factors in retinitis pigmentosa patients: pilot study after literature review. Biomedicines. 2019, 7, 94. 30.

11. Limoli PG, Limoli C, Vingolo EM, Scalinci SZ, Nebbioso M. Cell surgery and growth factors in dry age-related macular degeneration: visual prognosis and morphological study. Oncotarget. 2016, 7, 46913-46923.

12. Limoli PG, Limoli CSS, Morales MU, Vingolo EM. Mesenchymal stem cell surgery, rescue and regeneration in retinitis pigmentosa: clinical and rehabilitative prognostic aspects. Neurol. Neurosci. 2020, 38, 223-237.

13. Oner A, Gonen ZB, Sevim DG, Sinim Kahraman N, Unlu M. Six-month results of suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with optic atrophy: a phase 1/2 study. Ophthalmol.2019, 39, 2913-2922.

14. Lawrence N, Coleman WP 3rd. Liposuction. Am. Acad. Dermatol. 2002, 47, 105-108.

15. Yoshimura K, Shigeura T, Matsumoto D, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. Cell. Physiol. 2006, 208, 64-76.

16. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture...
expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013, 15, 641-648.

17. Mateo A, Perez de la Lastra J, Moreno A, Dusinsky R, Bilka F, Simon M, Horovska L, Llanes D. Biochemical characterization of antigens detected with anti-platelet monoclonal antibodies. Vet. Immunol. Immunopathol. 1996, 52, 363-70.

18. Ding SLS, Kumar S, Mok PL. Cellular reparative mechanisms of mesenchymal stem cells for retinal diseases. Int. J. Mol. Sci. 2017, 18, 1406.

19. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8, 315–317.

20. Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Paracrine-mediated neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: comparison with human bone marrow and adiposederived mesenchymal stem cells. PLoS ONE. 2014, 9, e109305.

21. Emre E, Yüksel N, Duruksu G, Pirhan D, Subaşı C, Erman G, Karaöz E. Neuroprotective effects of intravitreally transplanted adipose tissue and bone marrow-derived mesenchymal stem cells in an experimental ocular hypertension model. Cytotherapy. 2015, 17, 543–59.

22. Hofer HR, Tuan RS. Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies. Stem Cell Res. Ther. 2016, 7, 131.

23. Holan V, Hermankova B, Krulova M, Zajicova A. Cytokine interplay among the diseased retina, inflammatory cells and mesenchymal stem cells - a clue to stem cell-based therapy. World J. Stem Cells. 2019, 11, 957-967.

24. Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G. Stem cell-derived extracellular vesicles and immune-modulation. Cell Dev. Biol. 2016, 4, 83.

25. Lindroos B, Suuronen R, Miettinen S. The potential of adipose stem cells in regenerative medicine. Stem Cell Rev. Rep. 2011, 7, 269-91.

26. Hu ZL, Li N, Wei X, Tang L, Wang TH, Chen XM. Neuroprotective effects of BDNF and GDNF in intravitreally transplanted mesenchymal stem cells after optic nerve crush in mice. J. Ophthalmol. 2017, 10, 35-42.

27. Li X, Zhao S, Wang L. Therapeutic effect of adipose-derived stem cell transplantation on optic nerve injury in rats. Mol. Med. Rep. 2018, 17, 2529-2534.

28. Klassen H. Stem cells in clinical trials for treatment of retinal degeneration. Expert Opin. Biol. Ther. 2016, 16, 7-14.

29. Limoli PG, Vingolo EM, Limoli C, Nebbioso M. Antioxidant and biological properties of mesenchymal cells used for therapy in retinitis pigmentosa. Antioxidants (Basel, Switzerland). 2020, 9, 983.

30. Adak S, Magdalene D, Deshmukh S, Das D, Jaganathan BG. A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases. Stem Cell Rev Rep. 2021; Jan 6. doi: 10.1007/s12015-020-10090-
31. Siqueira RC, Messias A, Messias K, Arcieri RS, Ruiz MA, Souza NF, et al. Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells. Stem Cell Res Ther. 2015;6(1):29.

32. Ozmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Res Ther. 2020;11(1):353.

33. Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, et al. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014;56(1):81-9.